internatnew

Asia Pacific

Aspen’s Asia Pacific business comprises operations in Australia, New Zealand, ​​​​​​​the Philippines, Malaysia, Taiwan and Japan. Efforts are underway to establish an operation in China, following Aspen’s recent acquisition of anaesthetic and thrombosis products from AstraZeneca and GSK in this country. These operations supply a diversified portfolio of branded prescription, generic, OTC, consumer and infant nutritional products into Australia and New Zealand and the majority of countries in Asia. Certain tablets, liquids and semi-solids are produced at the Group’s manufacturing site in Melbourne, while other products for customers of this business are sourced from Aspen’s global manufacturing sites and accredited third-party manufacturers.

asiapac2

BUSINESS UNIT OVERVIEW

Asia Pasific
Key countries supplied to in this region

AustraliaChina • Hong Kong • Indonesia • Japan • Korea • Malaysia • New Zealand
Philippines • Singapore • Taiwan • Thailand • Vietnam

Contribution to Group
comparable gross revenue
asiagr1
Contribution to Group
comparable EBITA
asiagr2
Number of products launched from pipeline:

24 (2015: 34)

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:

0 – 2 years
USD1,35 billion

3 – 5 years
USD0,05 billion

Number of permanent employees:

772 (2015: 844)

Average staff turnover:

23% (2015: 24%)

Number of product recalls:

1 (2015: 1)
Number of work-related fatalities:

Nil (2015: Nil)

Carbon emissions:

Scope 1:
1 986 tCO2e
(2015: 2 907 tCO2e)

Scope 2:
16 427 tCO2e
(2015: 22 091 tCO2e)